Status:
COMPLETED
Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Conditions:
Herpes Genitalis
HIV Infection
Eligibility:
FEMALE
16+ years
Phase:
PHASE2
Brief Summary
Genital herpes is a long-life sexually transmitted diseases which infects a large proportion of women in Africa. Its clinical symptoms are painful sores on the genitals, which heals after a few days. ...
Detailed Description
Infection with Herpes Virus Simplex type 2 (HSV-2) is likely to represent the main cofactor involved in HIV transmission, either through clinical episodes or asymptomatic genital shedding. However, th...
Eligibility Criteria
Inclusion
- Infection with HIV-1 and HSV-2
- If required to take antiretrovirals according to WHO recommendations, should be on HAART for at least 4 months
- Written informed consent
Exclusion
- Pregnancy or willing to be pregnant during the next 6 months
- Breastfeeding
- Renal failure
- Expected non-compliance with follow-up or study treatment
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT00158509
Start Date
August 1 2004
End Date
July 1 2005
Last Update
June 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Hygiene du Centre Muraz
Bobo-Dioulasso, Burkina Faso